Wall Street is positive on Brickell Biotech Inc (BBI). On average, analysts give Brickell Biotech Inc a Strong Buy rating. The average price target is $5, which means analysts expect the stock to increase by 1251.35% over the next twelve months.
That average ranking earns Brickell Biotech Inc an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating BBI a Strong Buy today. Find out what this means to you and get the rest of the rankings on BBI!
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Brickell Biotech Inc Stock Today?
Brickell Biotech Inc (BBI) stock has fallen -30.74% while the S&P 500 is up 0.63% as of 9:56 AM on Thursday, Oct 28. BBI has fallen -$0.16 from the previous closing price of $0.54 on volume of 5,808,362 shares. Over the past year the S&P 500 is higher by 40.03% while BBI has fallen -27.45%. BBI lost -$0.76 per share the over the last 12 months.
Click Here to get the full Stock Report for Brickell Biotech Inc stock.